Hangzhou Just Biotherapeutics (Just China), a company focused on providing affordable biologic drugs, completed a $57 million Series B funding. Just China is developing a portfolio of innovative and biosimilar products. Founded in early 2016 as a joint venture with Just Biotherapeutics (Just) of Seattle, Just China was established with the goal of shortening the development process and reducing the manufacturing cost of biologic drugs. The B round was led by Temasek of Singapore and joined by existing investors Lilly Asia Ventures and ARCH Venture Partners.
Source: ChinaBio Today
